Y-mAbs Therapeutics, Inc.: accounts_receivable
| Value | {"amount": 19118000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2023-06-30) |
| Status | current |
| Entity | Y-mAbs Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T17:37:23.958445+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/1f3d708f-5017-4d26-954a-e02b235d513f
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001558370-23-014502Retrieved: 2026-08-19T17:37:23.958445+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001722964/accounts-receivable/2023-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/1f3d708f-5017-4d26-954a-e02b235d513f
History
- no predecessors — first report